Veit Zebralla

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Depression, anxiety, fatigue, and quality of life in a large sample of patients suffering from head and neck cancer in comparison with the general population

Carola Hammermüller, Andreas Hinz, Andreas Dietz et al. · BMC Cancer · 2021 · 128 citations · Full text

Medicine, Oncology, End-of-life Care +11

Dysphagia, voice problems, and pain in head and neck cancer patients

Veit Zebralla, Gunnar Wichmann, Markus Pirlich et al. · European Archives of Oto-Rhino-Laryngology · 2021 · 55 citations · Full text

Medicine, Oncology, Speech-language Pathology +16

Obtaining Patient-Reported Outcomes Electronically With “OncoFunction” in Head and Neck Cancer Patients During Aftercare

Veit Zebralla, Juliane Müller, Theresa Wald et al. · Frontiers in Oncology · 2020 · 25 citations · Full text

Pharmacy, Oncology, Radiation Oncology +15

Exploratory study of functional and psychological factors associated with employment status in patients with head and neck cancer

Laura Broemer, Michael Friedrich, Gunnar Wichmann et al. · Head & Neck · 2021 · 25 citations · Full text

Medicine, Oncology, Rehabilitation Medicine +15